Betta Pharma's PD-L1 Small Molecule Inhibitor for Solid Tumors or Lymphomas Obtained Clinical Approval

On January 15, CDE's official website showed that Betta Pharmaceuticals' PD-L1 small molecule inhibitor BPI-371153 was approved for clinical use and is intended for the treatment of patients with locally advanced or metastatic solid tumors or relapsed/refractory lymphoma

Preclinical studies have shown that high-dose BPI-371153 has stronger in vivo anti-tumor activity than PD-L1 monoclonal antibody, and significantly reduces tumor volume

Betta Pharmaceuticals submitted a listing application to the Hong Kong Stock Exchange on February 9, 2021, passed the Hong Kong Stock Exchange hearing on May 30, and submitted a prospectus to the Hong Kong Stock Exchange again on December 2.

Betta Pharmaceutical Pipeline

From: Hong Kong stock prospectus in December

According to the Insight database, there are currently 5 oral PD-L1 small molecule drugs under development in China

In addition, Fosun Pharma has also developed FH-2001, a dual-target PD-L1/FGFR inhibitor, which has not yet been registered to initiate clinical trials

Domestic PD-L1 small molecule drugs entering the clinic

From: Insight database (http://db.

Original title: Betta Pharmaceuticals’ PD-L1 small molecule inhibitor approved for clinical use